Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma

• Status: RECRUITING
• Trial end date: 2030-12-22

Summary

Add-on dostarlimab to chemoradiation with etoposide and cisplatin and radiotherapy can improve progression-free survival (PFS) compared with historical controls who were treated with chemoradiation alone in SCNECC

• Phase: PHASE2

Details

• Lead Sponsor: Chang Gung Memorial Hospital
• Treatments: dostarlimab